MedTrace Logo

Aripiprazole to Reduce Cocaine Relapse

NCT00276874 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-04-06

No results posted yet for this study

Summary

Despite the many behavioral and cognitive treatment therapies that exist for cocaine addiction, individuals who complete cocaine abuse treatment are still at high risk for relapsing. Aripiprazole, a medication that is currently used to treat schizophrenia, may be useful in preventing drug relapse in individuals addicted to cocaine. This three-part study will evaluate the interaction between aripiprazole and cocaine. It will also determine the safety and effectiveness of aripiprazole in preventing drug relapse among cocaine addicts.

Conditions

  • Cocaine-Related Disorders

Interventions

DRUG

Aripiprazole

Aripiprazole; 0-30 mg; oral; daily

DRUG

Placebos

Placebo; 0 mg; oral; daily

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Craig Rush

    lead OTHER

Principal Investigators

  • Craig R. Rush, PhD · University of Kentucky

  • Paul E Glaser, MD, PhD · University of Kentucky

  • Lon R. Hays, MD · University of Kentucky

  • Joshua A. Lile, PhD · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00276874 on ClinicalTrials.gov